Clinical Takeaway
In people at clinical high risk for psychosis, a single dose of CBD appeared to influence the relationship between hippocampal glutamate levels and prefrontal brain activity during verbal memory tasks. This suggests CBD may act on glutamate-related pathways in the hippocampus that are relevant to memory dysfunction seen in early psychosis risk states. These findings help clarify a potential neurochemical mechanism behind CBD’s effects, though larger trials are needed to confirm clinical relevance.
#18 A single dose of cannabidiol modulates the relationship between hippocampal glutamate and learning-related prefrontal activation in individuals at Clinical High Risk of Psychosis.
Citation: Shi Yiling et al.. A single dose of cannabidiol modulates the relationship between hippocampal glutamate and learning-related prefrontal activation in individuals at Clinical High Risk of Psychosis.. Psychiatry research. Neuroimaging. 2026. PMID: 41337954.
Design: 5 Journal: 0 N: 1 Recency: 3 Pop: 2 Human: 1 Risk: -2
This study elucidates a potential mechanistic pathway by which CBD exerts neuroprotective effects in CHR populations by demonstrating modulation of the glutamate-prefrontal circuit dysfunction implicated in psychosis progression. Understanding how CBD normalizes hippocampal glutamate dysregulation and its coupling with prefrontal learning-related activation could inform development of pharmacological interventions that target the neurobiological substrates of psychotic symptom emergence. These findings provide neurochemical and functional neuroimaging evidence that may support clinical translation of CBD into early intervention protocols for at-risk individuals.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Small sample — underpowered for subgroup analysis
Abstract: BACKGROUND: Cannabidiol (CBD) is being studied as a potential intervention for the people at clinical high risk for psychosis (CHR), though the mechanisms underlying its effects are not fully understood. Previous studies indicate that a single dose of CBD can normalize alterations in memory-related brain activation and modulate hippocampal glutamate levels in the early stages of psychosis. This study aimed to examine the acute effects of CBD on the relationship between hippocampal glutamate levels and brain activation during verbal memory in individuals at CHR. METHODS: A total of thirty-three participants (n = 33) at CHR were randomly assigned to receive a single 600 mg dose of CBD (CHR-CBD) or a placebo capsule (CHR-PLB). Age-matched healthy controls (HC) (n = 19) received no study drugs. Participants underwent MRI scanning while performing a verbal learning task, and proton magnetic resonance spectroscopy to measure hippocampal glutamate levels. Effect of group x hippocampal glutamate interactions on brain activation was tested. RESULTS: CHR-PLB showed positive correlation between hippocampal glutamate levels and dorsolateral prefrontal cortex (dlPFC) (Pcorr. = 0.0039) activation compared to HC during both verbal encoding and recall. Under a single dose of CBD, the glutamate-dlPFC activation relationship was negative and significantly different compared to placebo in CHR individuals (Pcorr. = 0.0001) during both verbal encoding and recall. The reversed correlation in CBD group was also observed in the parahippocampal gyrus (Pcorr. = 0.0022) and amygdala (Pcorr. = 0.0019) during verbal recall. CONCLUSIONS: These findings suggest that CBD may normalise disrupted hippocampal-prefrontal glutamatergic coupling in CHR, highlighting its potential to target the neurochemical mechanisms underlying cognitive impairment.
🧠 This study provides intriguing mechanistic insight into how a single CBD dose may normalize brain glutamate and prefrontal activation patterns in individuals at clinical high risk for psychosis, a finding that could eventually inform prevention strategies. However, several important caveats warrant consideration: the study examines acute effects from a single dose rather than sustained treatment, the CHR population is heterogeneous with variable progression to psychosis, and neuroimaging biomarkers do not always correlate with clinical outcomes or symptom burden. The relationship between hippocampal glutamate modulation and actual prevention of psychotic transition remains unclear and will require longer-term prospective studies with clinical endpoint assessment. For now, clinicians should view CBD as a promising research avenue rather than an established preventive intervention for CHR patients, while acknowledging that we still lack clarity on optimal dosing, duration of therapy, and which CHR subgroups might benefit most. In practice, if you are considering CBD for a CHR patient, frame it as part of an informed